India Pharma Outlook Team | Wednesday, 07 January 2026
Biocon Ltd announced Tuesday that its unit Biocon Biologics oncology biosimilars will expand with three new cancer therapies aimed at strengthening its presence in the global oncology market.
With a regulatory filing, the company announced that it would launch biosimilars to Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo), and Pembrolizumab (Keytruda) in 2026 at the JP Morgan Healthcare Conference in San Francisco.
These newcomings have left Biocon Biologics to have a more comprehensive and extensive oncology portfolio. The company claims that the action will assist in expanding the access to important cancer therapies by giving more affordable options to expensive biologics, which is a large trend in the industry as more biologics go off patent.
Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation
The new assets have been cited as some of the biggest oncology biologics that are likely to lose exclusivity in the next five years. They will form a part of the already existing 17 oncology medicines of Biocon Biologics. It already has that portfolio with Pertuzumab (Perjeta) which it has recently filed to the US FDA and a variety of small-molecule cancer therapies.
Market context underscores the opportunity. Global sales of Keytruda reached USD 29.5 billion in 2024, while Opdivo recorded USD 9.3 billion. Combined sales for Herceptin SC and Herceptin HYLECTA were USD 1.72 billion, highlighting the commercial potential for biosimilar versions of these top?selling drugs.
“Guided by a science?led, R&D approach, we are advancing a strong pipeline with 17 oncology assets to meet varied patient needs,” said Biocon Biologics CEO and Managing Director Shreehas Tambe, underlining the company’s commitment to innovation and patient access in oncology care.
.jpg)
.jpg)
